Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SY-LB-35 是骨形态发生蛋白 (BMP) 受体的有效激动剂。SY-LB-35 可以刺激 C2C12 成肌细胞系中细胞数量和细胞活力的显著增加,并引起细胞周期向 S 期和 G2/M 期转变。SY-LB-35 刺激典型的 Smad 和非典型的 PI3K/Akt、ERK、p38和 JNK 胞内信号通路。
产品描述 | SY-LB-35, a potent bone morphogenetic protein (BMP) receptor agonist, significantly enhances cell number and viability in the C2C12 myoblast cell line. It promotes cell cycle progression, particularly towards the S and G2/M phases. Additionally, SY-LB-35 activates both canonical Smad and non-canonical intracellular signaling pathways, including PI3K/Akt, ERK, p38, and JNK [1]. |
体外活性 | SY-LB-35 (0.01-1000 μM; 24 h) stimulates significant increases in cell number and cell viability of C2C12 myoblast cell line [1]. SY-LB-35 (0.01-10 μM; 30 min or 15 min) stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulates the phosphorylation and activation of PI3K in the C2C12 cells [1]. SY-LB-35 (0.01-10 μM; 24 h) leads the cell cycle shifting to S and G2/M phases in the C2C12 cells [1]. Cell Viability Assay [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1, 10, 100 and 1000 μM Incubation Time: 24 h Result: Stimulated significant increases in cell number and cell viability. Western Blot Analysis [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 30 or 15 min Result: Stimulated Smad phosphorylation and nuclear translocation, activated the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulated the phosphorylation and activation of PI3K in the C2C12 cells. Cell Cycle Analysis [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 24 h Result: Caused the cell cycle shifting to S and G2/M phases. |
分子量 | 249.27 |
分子式 | C15H11N3O |
CAS No. | 2603461-70-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SY-LB-35 2603461-70-5 Inhibitor inhibitor inhibit